In This Article:
As the European markets navigate the complexities of U.S. trade policy uncertainties, recent economic measures by Germany and the European Union have provided some stability amidst volatility. Penny stocks, often overlooked due to their association with smaller or newer companies, continue to offer intriguing potential for investors seeking growth at lower price points. Despite being considered a relic of past market eras, these stocks can still present significant opportunities when backed by strong financials and solid fundamentals.
Top 10 Penny Stocks In Europe
Name | Share Price | Market Cap | Financial Health Rating |
Angler Gaming (NGM:ANGL) | SEK3.70 | SEK277.44M | ★★★★★★ |
Netgem (ENXTPA:ALNTG) | €0.99 | €33.15M | ★★★★★★ |
Hifab Group (OM:HIFA B) | SEK3.98 | SEK242.14M | ★★★★★★ |
High (ENXTPA:HCO) | €2.67 | €52.44M | ★★★★★★ |
Transferator (NGM:TRAN A) | SEK2.24 | SEK210.19M | ★★★★★☆ |
Deceuninck (ENXTBR:DECB) | €2.215 | €306.55M | ★★★★★★ |
I.M.D. International Medical Devices (BIT:IMD) | €1.38 | €23.9M | ★★★★★☆ |
Bredband2 i Skandinavien (OM:BRE2) | SEK2.08 | SEK1.99B | ★★★★☆☆ |
Riber (ENXTPA:ALRIB) | €3.04 | €63.7M | ★★★★★☆ |
IMS (WSE:IMS) | PLN3.66 | PLN124.05M | ★★★★☆☆ |
Click here to see the full list of 433 stocks from our European Penny Stocks screener.
Below we spotlight a couple of our favorites from our exclusive screener.
Horisont Energi
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Horisont Energi AS is a clean energy company focused on producing and selling clean ammonia and hydrogen in Norway, with a market cap of NOK37.95 million.
Operations: Horisont Energi AS has not reported any revenue segments.
Market Cap: NOK37.95M
Horisont Energi AS, with a market cap of NOK37.95 million, is pre-revenue and currently unprofitable. The company's short-term assets significantly exceed both its short-term and long-term liabilities, indicating a strong liquidity position despite having less than a year of cash runway. Recent board changes include the appointment of Frode Sigurd Berg as Chair, bringing extensive experience in strategic processes. However, the board's average tenure is under one year, suggesting limited experience. The stock has experienced high volatility recently and remains debt-free but faces challenges with declining earnings over five years.
-
Click to explore a detailed breakdown of our findings in Horisont Energi's financial health report.
-
Assess Horisont Energi's previous results with our detailed historical performance reports.
Isofol Medical
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Isofol Medical AB is a clinical stage biotech company focused on developing, commercializing, and selling oncology drugs in Sweden and internationally, with a market cap of SEK262.95 million.